This educational activity will provide clinicians with the latest evidence on BCMA-targeted therapies for relapsed/refractory multiple myeloma (RRMM), with a focus on the role of bispecific antibodies in the evolving treatment landscape. Faculty will review clinical data supporting current and emerging agents, discuss guideline-based approaches to patient selection and treatment sequencing, and share practical strategies for recognizing, preventing, and managing adverse events associated with bispecific antibody therapy. Through expert insights and evidence-based recommendations, learners will gain the knowledge and confidence to optimize individualized care for patients with RRMM.

RELEASED DATE: August 14, 2026
EXPIRATION DATE: August 14, 2027

The activity is designed to enhance participants’ understanding and clinical competence in several critical areas, including the efficacy and safety profiles of bispecific antibodies (BsAbs) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The program will also examine the identification and management of adverse events associated with targeted therapies, and the implementation of effective multidisciplinary care strategies. Participants will explore approaches to delivering comprehensive, coordinated care through collaboration across the care team to optimize outcomes for patients with R/R DLBCL and FL.

RELEASED DATE: August 14, 2026
EXPIRATION DATE: August 14, 2027

This podcast highlights key data presented at ASCO 2026 in multiple myeloma. The multiple myeloma podcast features a discussion between Dr. Joshua Richter and an advanced practice provider, emphasizing the value of multidisciplinary care and the practical application of emerging evidence. Designed for busy healthcare professionals, the on-demand format provides concise, accessible education that can be completed during commutes or other downtime while supporting knowledge retention and clinical practice.

RELEASED DATE: July 10, 2026
EXPIRATION DATE: July 24, 2027

This program is designed to address persistent clinical gaps in the management of nonmelanoma skin cancers (NMSCs), particularly in identifying and treating high-risk disease. The program is structured to improve clinicians’ knowledge, competence, and confidence by enabling them to identify key diagnostic and stratification criteria to promptly and accurately recognize high-risk NMSC. Building on this foundation, the education integrates current clinical data for emerging neoadjuvant and adjuvant immunotherapies, supporting clinicians in incorporating these approaches into treatment strategies to optimize surgical outcomes and reduce recurrence risk. Additionally, the program emphasizes the importance of coordinated, patient-centered care by developing strategies for clinicians to work effectively within the multidisciplinary team and engage patients in shared decision-making, ultimately enhancing communication, care alignment, and overall outcomes in high-risk NMSC management.

RELEASED DATE: June 05, 2026
EXPIRATION DATE: June 05, 2027

This CME-accredited video presentation provides a concise, approximately 15-minute deep dive into first-line therapy for non-driver-mutated, metastatic non-small cell lung cancer. During this activity, a lung cancer expert reviews diagnosis and workup best practices, current guideline recommendations and emerging evidence for first-line treatment, immune-related adverse event management, and strategies to improve patient outcomes through shared decision-making and multidisciplinary collaboration. This program is delivered via the immersive ENCOMPASS platform, which offers access to a range of engaging resources (for example, animations, infographic-driven slides, and a personalized poster creation tool) designed to support your practice.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

This CME-accredited video presentation provides a concise, approximately 15-minute deep dive into the management of advanced melanoma. During this activity, a melanoma expert reviews diagnosis and workup best practices, current guideline recommendations, and emerging evidence for first-line treatment, as well as strategies to improve patient outcomes through shared decision-making and multidisciplinary collaboration. This program is delivered via the immersive ENCOMPASS platform, which offers access to a range of engaging resources (for example, animations, infographic-driven slides, and a personalized poster creation tool) designed to support your practice.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

This CME-accredited micro-learning activity introduces healthcare professionals to an immersive AR Mobile Application designed to enhance patient-centered care in relapsed/refractory multiple myeloma (R/R MM). Through a brief faculty-led demonstration, learners will explore the practical use of AR technology to reinforce clinical concepts, support shared decision-making, and improve communication with patients and colleagues.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

This program is designed to address persistent clinical gaps in the management of nonmelanoma skin cancers (NMSCs), particularly in identifying and treating high-risk disease. The program is structured to improve clinicians’ knowledge, competence, and confidence by enabling them to identify key diagnostic and stratification criteria to promptly and accurately recognize high-risk NMSC. Building on this foundation, the education integrates current clinical data for emerging neoadjuvant and adjuvant immunotherapies, supporting clinicians in incorporating these approaches into treatment strategies to optimize surgical outcomes and reduce recurrence risk. Additionally, the program emphasizes the importance of coordinated, patient-centered care by developing strategies for clinicians to work effectively within the multidisciplinary team and engage patients in shared decision-making, ultimately enhancing communication, care alignment, and overall outcomes in high-risk NMSC management.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

This program is designed to address persistent clinical gaps in the management of nonmelanoma skin cancers (NMSCs), particularly in identifying and treating high-risk disease. The program is structured to improve clinicians’ knowledge, competence, and confidence by enabling them to identify key diagnostic and stratification criteria to promptly and accurately recognize high-risk NMSC. Building on this foundation, the education integrates current clinical data for emerging neoadjuvant and adjuvant immunotherapies, supporting clinicians in incorporating these approaches into treatment strategies to optimize surgical outcomes and reduce recurrence risk. Additionally, the program emphasizes the importance of coordinated, patient-centered care by developing strategies for clinicians to work effectively within the multidisciplinary team and engage patients in shared decision-making, ultimately enhancing communication, care alignment, and overall outcomes in high-risk NMSC management.

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

This enduring activity is designed for healthcare professionals involved in the management of patients with non-melanoma skin cancers (NMSCs). This case-based presentation—led by expert faculty and enriched with Patient Spotlight Videos—address complex and evolving NMSC cases to enhance clinical decision-making and patient outcomes. Participants will gain practical insights into modern treatment selection, the expanding role of immune checkpoint inhibitors, and effective multidisciplinary and patient-centered care strategies. Supporting resources, including an engaging Whiteboard Animation, will reinforce key concepts, promoting sustained improvement in care delivery across academic and community dermatology practices nationwide.

RELEASED DATE: January 23, 2026
EXPIRATION DATE: January 23, 2027